gip/glp-1 receptor agonist New Weight-Loss Drugs Are Poised to Upend Preventive Cardiology Care in Patients With Obesity and Overweight Main physiological actions of the
Description
10 , eaat3392 (2018)
Rural and underserved communities may face additional barriers to accessing both the medications and the comprehensive monitoring required for safe use
While most are approved for the management of type 2 diabetes, some formulations, such as semaglutide (Wegovy) and tirzepatide (Zepbound), have also been approved for chronic weight management in adults with obesity or overweight
Nature 575 , 669673 (2019)
Arnold AC
Conclusion GLP-1RA and SGLT2-I are efficacious second-line treatments for T2DM with limited risk of hypoglycemia and positive or neutral effects on CV risk, weight, and BP
